BioSpace News Archive

Business

Ordaōs and NonExomics Announce Research Collaboration

Ordaōs partners with NonExomics to create customized mini-proteins.

September 28, 2022
·
3 min read
BioMidwest

Johnson & Johnson Vision Expands Access to Myopia Management for More Patients with Abiliti™ Overnight Lenses

Johnson & Johnson Vision announced FDA approval of an expanded range of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management, now up to 6.00 diopters.

September 28, 2022
·
7 min read
As part of its strategy for global growth and the enhancement of internal expertise, focusing on biotech, Olon is delighted to present its two-year plan for investment in the Settimo Torinese Biotech Centre (Italy)

The plan, worth €30 million, will be implemented over the following two-year period, with the aim of significantly expanding the capacity and expertise of the Settimo Torinese Biotech Hub.

September 28, 2022
·
1 min read
Business

Castor Appoints Andrew Sadler as Chief Product & Technology Officer

Castor today announced the appointment of Andrew Sadler as Chief Product & Technology Officer (CPTO).

September 28, 2022
·
2 min read
Drug Development

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

September 28, 2022
·
7 min read
Biotech Bay

Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics

Sudo Biosciences today announced the close of $37M in Series A financing led by Frazier Life Sciences (“Frazier”) and Velosity Capital.

September 28, 2022
·
3 min read
Drug Development

Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE, a Phase 2 Clinical Trial of SPI-62 for Cushing’s Syndrome

Sparrow Pharmaceuticals today announced that the first patient has been dosed in the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome.

September 28, 2022
·
3 min read
Drug Development

Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Azura Ophthalmics Ltd. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study protocol of AZR-MD-001 in Meibomian Gland Dysfunction (MGD).

September 28, 2022
·
4 min read
Drug Development

Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody

Lassen Therapeutics today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody.

September 28, 2022
·
2 min read
Deals

Transcat Establishes Calibration Presence in Ireland with Acquisition of Complete Calibrations and acquires Cleveland-based e2b Calibration

Transcat, Inc. announced that it has purchased all of the capital stock of privately-held Galium Limited, effective September 28, 2022.

September 28, 2022
·
6 min read